Results 31 to 40 of about 74,951 (264)

Targeted radiotherapy of neuroblastoma: future directions [PDF]

, 2017
No abstract ...
Gaze, Mark N., Mairs, Robert, Nile, Donna L., Rae, Colin, Tesson, Mathias   +4 more
core   +2 more sources

Duodenal carcinoid tumour – a case report [PDF]

, 2020
Duodenal carcinoids are rare tumours of the small intestine with heterogenous clinical and pathological characteristics. The long-term prognosis is very good if discovered in the early stages.
Alexescu, Teodora Gabriela, Buchman, Cristina, Domsa, Iacob, Milaciu, Mircea, Negrean, Vasile, Orasan, Olga Hilda, Para, Ioana, Perne, Mirela Georgiana   +7 more
core   +2 more sources

Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

, 2017
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
Abraham, Berg, Bruns, Church, Colao, Colao, Combes, Cozzi, Dowling, Dunning, Feelders, Freda, Gadelha, Henry, Hofland, Hubina, Hussaini, Jaffe, Katznelson, Kurosaki, Lamb, Laron, Ma, Meij, Meij, Myers, Niessen, Niessen, Niessen, Patel, Petersenn, Peterson, Reubi, Reusch, Reusch, Sathyapalan, Schaefer, Scudder, Shanik, Slingerland, Slingerland, Theodoropoulou, Tyson, Zambre   +43 more
core   +3 more sources

Somatostatin and somatostatin receptors in Cushing's disease [PDF]

Molecular and Cellular Endocrinology, 2008
Cushing's disease is caused by an ACTH secreting pituitary adenoma. Surgery is the treatment of choice and cure rates between 60 and 90% are reported. For patients in which surgery fails, effective medical treatment options are needed. Somatostatin (SS) receptors (sst) are expressed on normal and tumoral corticotroph cells.
openaire   +4 more sources

Expression of somatostatin receptors in hemangioblastomas associated with von Hippel-Lindau disease as a novel diagnostic, therapeutic, and follow-up opportunity: A case report and literature review

Archives of Endocrinology and Metabolism
SUMMARY Hemangioblastomas associated with von Hippel-Lindau (VHL) disease are frequently multiple and recur during prolonged follow-up. Currently, no systemic treatment is available for these tumors.
Eloá Pereira Brabo, Sergio Altino de Almeida, Patrícia Piazza Rafful, Paulo Henrique Rosado-de-Castro, Leonardo Vieira Neto   +4 more
doaj   +1 more source

Molecular imaging for neuroendocrine tumours

Swiss Medical Weekly, 2019
Molecular imaging has found numerous applications in oncology as many tumours express or activate tumour specific target molecules or pathways. This relatively new imaging technique results in a better localisation of tumours and improved tumour ...
Kwadwo Antwi, Guillaume Nicolas, Damian Wild, Emanuel Christ   +3 more
doaj   +1 more source

The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowth. [PDF]

PLoS ONE, 2009
The neuropeptide somatostatin has been suggested to play an important role during neuronal development in addition to its established modulatory impact on neuroendocrine, motor and cognitive functions in adults.
Virginia Le Verche, Angela M Kaindl, Catherine Verney, Zsolt Csaba, Stéphane Peineau, Paul Olivier, Homa Adle-Biassette, Christophe Leterrier, Tania Vitalis, Julie Renaud, Bénédicte Dargent, Pierre Gressens, Pascal Dournaud   +12 more
doaj   +1 more source

Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis

Molecular Therapy: Oncolytics, 2023
Tumor-specific overexpression of receptors enables a variety of targeted cancer therapies, exemplified by peptide-receptor radiotherapy (PRRT) for somatostatin receptor (SSTR)-positive neuroendocrine tumors.
Kathryn Ottolino-Perry, David Mealiea, Clara Sellers, Sergio A. Acuna, Fernando A. Angarita, Lili Okamoto, Deborah Scollard, Mihaela Ginj, Raymond Reilly, J. Andrea McCart   +9 more
doaj   +1 more source

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +1 more source

Thyroxine-binding globulin: investigation of microheterogeneity [PDF]

, 1981
Preparations of T4-binding globulin (TBG) from human serum was performed using only two affinity chromatography steps. Purity of the protein was demonstrated by a single band in overloaded disc and sodium dodecyl sulfate electrophoresis, equimolar ...
Gärtner, Roland, Henze, R., Horn, K., Pickardt, C. R., Scriba, Peter Christian   +4 more
core   +1 more source